https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-1986
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-19862021-06-29 00:00:002021-06-29 00:00:00A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-28 / Front Cell Dev Biol 2021;9:686544
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-28 / Front Cell Dev Biol 2021;9:6865442021-06-28 00:00:002021-06-28 00:00:00Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-58402021-06-18 00:00:002023-01-31 13:08:35Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-1734
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-17342021-06-17 00:00:002023-01-31 13:09:00Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)2021-06-09 00:00:002021-06-09 00:00:00Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-04 / J Clin Oncol 39, 2021 (suppl 15; abstr e14512)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-04 / J Clin Oncol 39, 2021 (suppl 15; abstr e14512)2021-06-04 00:00:002021-06-04 00:00:00A phase I study to evaluate the safety and effectiveness of neoantigen-based personalized dendritic cell vaccine in patients with advanced solid tumors.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)2021-06-04 00:00:002021-06-04 00:00:00Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
